Novalar reaches agreement

May 17, 2010
H.A. Systems will distribute OraVerse in Israel.

SAN DIEGO, California--Novalar Pharmaceuticals has announced entering into an agreement with H.A. Systems Dental Imports to distribute OraVerse® in Israel and the Palestinian Territories.

Under the terms of the agreement, H.A. Systems will file the necessary documentation for regulatory approval of OraVerse with the Israel Ministry of Health. Upon approval, H.A. Systems--based in Ramat Gan, Israel--will have exclusive rights to promote and distribute OraVerse to dentists in the territory through the company’s established dental franchise and sales force.

OraVerse is a local anesthesia reversal agent that accelerates the return of normal sensation and function following routine dental procedures. OraVerse is approved for use in the U.S. by the Food and Drug Administration and sold by Novalar direct to dentists in the U.S.

“This collaboration is yet another important step in expanding Novalar’s international commercialization efforts,” noted Donna Janson, president and chief executive officer of Novalar.

“As Israel offers patients exceptional dental care, this market is extremely attractive for us. H.A. Systems has established itself as a leader in the field of tissue regeneration, dental implantology, and new dental technologies, which makes it the perfect partner to launch OraVerse into Israel.”

Added Fanny Gross, president and chief executive officer of H.A. Systems: “H.A. Systems has significant experience launching new and innovative dental products and providing continuing education and scientific support to the profession. We also have the necessary infrastructure and existing relationships within the local dental community for the successful launch of OraVerse in Israel and we look forward to offering this unique product to our customers.”

For more information, visit

To read more about OraVerse, go to

To comment on this subject, go to